Article
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Blood advances - 13 Oct 2020
Voso Maria Teresa, Larson Richard A, Jones Dan, Marcucci Guido, Prior Thomas, Krauter Jürgen, Heuser Michael, Lavorgna Serena, Nomdedeu Josep, Geyer Susan M, Walker Alison, Wei Andrew H, Sierra Jorge, Sanz Miguel A, Brandwein Joseph M, de Witte Theo M, Jansen Joop H, Niederwieser Dietger, Appelbaum Frederick R, Medeiros Bruno C, Tallman Martin S, Schlenk Richard F, Ganser Arnold, Amadori Sergio, Cheng Yuan, Chen YinMiao, Pallaud Celine, Du Ling, Piciocchi Alfonso, Ehninger Gerhard, Byrd John, Thiede Christian, Döhner Konstanze, Stone Richard M, Döhner Hartmut, Bloomfield Clara D, Lo-Coco Francesco
Abstract excerpt
The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase...
Topics
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Nucleophosmin
- Staurosporine
- fms-Like Tyrosine Kinase 3